Danish Pharma Stock News

CK Hutchison has taken A.P. Møller - Mærsk to arbitration in London over Panama port assets after APM Terminals was appointed interim operator, adding legal complexity to an already politically sensitive dispute involving Panama, the US and China. At the same time, Maersk is confronting fresh uncertainty in the Strait of Hormuz as Iran seeks cryptocurrency toll payments during a temporary ceasefire, underlining how geopolitical and regulatory shifts can directly affect the company’s global...

Why Schouw’s 2026 buy-back matters for shareholders Aktieselskabet Schouw (CPSE:SCHO) has kicked off a share buy-back programme for up to DKK 240 million running through 2026, with treasury holdings now at 2,342,076 shares (9.37% of outstanding capital). See our latest analysis for Aktieselskabet Schouw. At a share price of DKK666.0, Schouw has seen a 7.42% 1 month share price return while the 1 year total shareholder return of 20.32% points to solid longer term gains, with the new buy back...

As European markets experience a positive upswing, with the STOXX Europe 600 Index gaining nearly 4% amid easing concerns over Middle East tensions, investors are increasingly looking towards dividend stocks as a stable income source amidst economic uncertainties. In such an environment, selecting dividend stocks that offer consistent yields above 3.2% can provide both income and potential capital appreciation, making them attractive options for those seeking to balance risk and reward in...

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see North Media...

If you are wondering whether Novo Nordisk's current share price represents value or a premium for quality, this article walks through what the numbers indicate about the stock. Novo Nordisk shares last closed at DKK 241.2, with returns of 1.8% over 7 days, a 5.2% decline over 30 days, a 27.0% decline year to date, a 37.5% decline over 1 year, and a 52.8% decline over 3 years, alongside a 22.2% gain over 5 years. Recent coverage has focused on Novo Nordisk's role in the pharmaceuticals and...

Tryg (CPSE:TRYG) is in focus after its board launched a share buyback programme of up to DKK 1.0b, and shareholders also renewed long term authorisations for potential future share capital increases. See our latest analysis for Tryg. At a share price of DKK155.1, the stock has seen a 1 day share price return of 1.24%, while the 1 year total shareholder return of 8.43% contrasts with a weaker year to date share price return of 6.06%. This suggests momentum has softened recently despite the...

Carlsberg stock reaction and recent performance snapshot Carlsberg (CPSE:CARL B) has moved without a clear single news catalyst. This has left investors to focus on recent share performance, valuation signals and the company’s latest reported financial profile. Over the past month, the share price shows a return of about 10%, while the past 3 months are roughly flat. Year to date, Carlsberg’s total return is around 1% lower, with a 1 year total return close to 1%. See our latest analysis for...

Vestas Wind Systems (CPSE:VWS) has drawn fresh investor attention after announcing a series of new onshore wind turbine orders across Europe and the USA, along with plans for a new nacelle and hub factory in Scotland. See our latest analysis for Vestas Wind Systems. These new orders and the planned Scotland factory come after a 30 day share price return of 18.76% and a 1 year total shareholder return of 111.42%, although the 5 year total shareholder return is 21.69% lower. If this surge in...

Park Street A/S ( CPH:PARKST A ) just released a solid earnings report, and the stock displayed some strength. Despite...

Hims & Hers Health has renewed its partnership with Novo Nordisk to offer obesity drugs Wegovy and Ozempic through its telehealth platform. The agreement restores access to multiple dosages of these medications for Hims & Hers users, with a focus on broader affordability and availability. The move comes as demand for obesity treatments remains high and digital channels play a larger role in how patients obtain prescriptions. Novo Nordisk, listed as CPSE:NOVO B, is tying this distribution...

AGM decisions reshape Danske Bank’s capital framework Danske Bank (CPSE:DANSKE) has approved several changes to its Articles of Association at the 26 March 2026 AGM, including a share capital reduction through cancellation of shares and updated capital authorisations. See our latest analysis for Danske Bank. The AGM news comes after a mixed share price pattern, with a recent 1 day share price return of 2.15% and a 1 year total shareholder return of 76.87%. This suggests momentum remains...

Why Ringkjøbing Landbobank Is On Investors’ Radar Ringkjøbing Landbobank (CPSE:RILBA) has drawn attention after a share price of DKK 1,564 and a stated intrinsic discount of 39.2%, prompting investors to reassess how its current valuation lines up with fundamentals. See our latest analysis for Ringkjøbing Landbobank. Recent trading has been relatively steady, with the latest share price at DKK 1,564 and short term share price returns in low single digits, while the 1 year total shareholder...

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

As European markets navigate the complexities of Middle East tensions and energy market volatility, the pan-European STOXX Europe 600 Index has shown resilience, ending the week up 3.92% in local currency terms. This positive sentiment is supported by hopes for a shorter-lived conflict and is reflected in gains across major stock indexes like Germany's DAX and Italy's FTSE MIB. In this environment, identifying promising stocks involves looking for companies with strong fundamentals that can...

Why FLSmidth (CPSE:FLS) is in focus right now FLSmidth (CPSE:FLS) has just completed the sale of its former corporate headquarters in Valby, Denmark, a previously flagged transaction that brings in net cash proceeds and an accounting gain in Q1 2026. See our latest analysis for FLSmidth. The DKK504.5 share price has climbed 4.4% over the last day and 8.9% over 90 days. The 1 year total shareholder return of 86.6% points to strong longer term momentum, even after a recent 4.4% 1 month share...

Dividend decision and why it matters now Novozymes (CPSE:NSIS B) has drawn fresh investor attention after its Annual General Meeting approved an ordinary dividend of DKK 4.25 per A and B share, a higher regular payout compared with previous years. This move to distribute more cash gives you an additional lens on the stock, alongside its recent share price performance and the company’s position across food, bioenergy, household care, agriculture and health focused biosolutions. See our latest...

ALK-Abelló (CPSE:ALK B) is back in focus after the European Commission approved EURneffy 1 mg, a needle free adrenaline treatment that opens wider EU access for children aged 4 and older with severe allergies. See our latest analysis for ALK-Abelló. The EURneffy approval lands after a strong run for ALK-Abelló, with the latest share price at DKK205.8, a 1 year total shareholder return of 46.96% and a 3 year total shareholder return of 97.12%. However, shorter term share price returns suggest...

It looks like TCM Group A/S ( CPH:TCM ) is about to go ex-dividend in the next 4 days. The ex-dividend date is two...

Alm. Brand A/S ( CPH:ALMB ) stock is about to trade ex-dividend in four days. The ex-dividend date is usually set to be...

Last week's earnings announcement from Harboes Bryggeri A/S ( CPH:HARB B ) was disappointing to investors, with a...

Zealand Pharma (CPSE:ZEAL) recently announced a new research hub in Cambridge, Massachusetts. This facility will become its primary U.S. base and will focus on AI-driven drug discovery, advanced automation, and new therapeutic modalities. See our latest analysis for Zealand Pharma. The share price is DKK298.0 after a 1-day share price return of 1.02% and a 7-day share price return of 3.47%. However, the 30-day and year-to-date share price returns of -19.28% and -35.23% suggest recent momentum...

Regulatory update: EMA review for paediatric mpox and smallpox use Bavarian Nordic (CPSE:BAVA) has filed Phase 2 data with the European Medicines Agency to extend its MVA-BN mpox and smallpox vaccine indication to children aged 2 to 11. This filing highlights a potential shift in the product’s approved patient group. See our latest analysis for Bavarian Nordic. The latest EMA filing comes as Bavarian Nordic’s DKK195.7 share price sits on a 4.3% 1 month share price return and a 36.7% 1 year...

In late March 2026, Vestas Wind Systems announced a series of new wind turbine orders across Germany, France, the UK and the USA, alongside long-term service agreements and deliveries stretching from 2026 to 2028, and separately revealed plans for a more than €250 million nacelle and hub factory in Scotland targeting its V236-15.0 MW offshore turbines. Taken together, the fresh onshore order intake and the conditional Scottish offshore factory plan underline how Vestas is tying near-term...